Topic: myelofibrosis

Incyte pens cancer I-O pact with UPenn cancer center

Just 12 months ago, Incyte was hit with a major trial setback when its JAK inhibition drug for solid tumors flopped a key test. Since then the biotech has been looking to I-O combos, and today it has broadened its reach with a new cancer immunotherapy deal with the University of Pennsylvania.

5. Gilead Sciences

Gilead Sciences could at one time do no wrong, but then sales of its hep C meds slowed and it hit some major trial setbacks. Now, the biotech faces increasingly loud questions about what its next Big Thing will be.